Eagle Vision Pharmaceutical

Eagle Vision Pharmaceutical Corporation offers a novel, clinical-stage molecular imaging opportunity that enhances the vast potential of widely-used magnetic resonance imaging (MRI), revolutionizing the diagnosis and management of chronic human diseases ("Magnetic PET").SeeMoreTM (EVP1001) is a patented, first-in-class intravenous manganese-based intracellular agent targeting metabolically active cells. Leveraging MRI’s high-resolution tissue differentiation, it provides superior diagnostic accuracy and early assessment of treatment response to improve patient management. EVP1001 distinguishes healthy from abnormal tissues in a single, non-invasive examination without radiation or radioactive substances. Preclinical and clinical results have confirmed its suitability for a wide range of applications, including cancer, chronic liver disease, and heart disease evaluation. Currently, world-class medical centers are conducting advanced clinical trials using EVP1001 to assess stem cell therapy for the heart.